Until recently, microbicide research has focused on vaginal microbicides. Recent initiatives and ongoing studies highlight the need for safe and effective rectal microbicides as part of an essential HIV prevention toolkit.
Ready, Set, Rectal Microbicides: An Update on Rectal Microbicide Research and Advocacy
African Women’s Civil Society Consultation on HIV Risk and Hormonal Contraceptives
More than 40 women representing HIV prevention advocates, reproductive health service providers, and women living with HIV from Kenya, South Africa, Rwanda, Uganda and Zimbabwe met to review and discuss the existing data on hormonal contraceptive use and HIV risk.
AIDS Vaccine Science for Busy Advocates – Current AIDS Vaccine R&D Pipeline
One-pager reviewing what we’ve learned from previous efficacy trials, the product pipeline and where we are today and future directions toward finding a vaccine that works.
Multipurpose Prevention Technologies (MPTs): An introductory factsheet
This introductory 2-page document makes the case for why women need prevention options that protect them against multiple risks—HIV, STIs and/or pregnancy—and discusses the products that are being studied for this purpose. The factsheet is part of a series on emerging HIV prevention strategies.
Ugandan Service Provider Perspectives on the WHO Recommendation on Hormonal Contraceptives and HIV Risk
This abstract poster, developed by 2012 AVAC Advocacy Fellow Lydia Mulwanyi-Mukombe and her Host, Lillian Mworeko, describes key findings from consultations with Uganda service providers. It reports how providers were planning to use the new WHO guidance and makes recommendations for how to protect and inform women in light of the potential HIV risk associated with hormonal contraceptive use.
Women and HIV Prevention Research: Designing, testing and marketing products to improve adherence
The fourth webinar in AVAC’s Research & Reality series, a year-long dialogue about prevention research and advocacy, this webinar provided a forum to learn about and discuss key issues around women and the HIV prevention agenda, including challenges around marketing of and adherence to new prevention options. Click for speaker details, slides and audio.
Capitalizing on Scientific Progress: Investment in HIV Prevention R&D in 2010
This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. The 2011 report describes the funding environment in the wake of a number of the findings of efficacy in the RV144, CAPRISA, iPrEx and HPTN 025 trials and calls for sustained funding to build on these results.
MPT Product Development & Regulatory Issues 101
This webinar featured experts Dr. Joe Romano (NWJ Group/CAMI) and Dr. Jim Turpin (NIAID) who provided updates on the state of multipurpose prevention technologies (MPTs) research, the pipeline and potential manufacturing and regulatory pathways. MPTs are being developed to simultaneously prevent unintended pregnancy and protect against HIV and other sexually transmitted infections.Click to access the webinar slides and recording.
The HIV Prevention Research-to-Rollout Continuum
AVAC Playbook 2013–2014: Global goals and priorities
The AVAC’s Playbook is a concise look at global goals related to ten areas that are critical to ending the AIDS epidemic. The squares contain long-term goals; in the circles we have laid out priorities for 2014. Working with our partners, we develop and implement advocacy strategies to get us closer to these goals.